Skip to main content
NeuroWiki
Thrombectomy

REVASCAT Trial: Solitaire Thrombectomy Within 8 Hours

In patients with anterior circulation LVO presenting up to 8 hours from onset who were ineligible for or refractory to IV alteplase, does Solitaire stent-retriever thrombectomy added to medical therapy improve functional outcome at 90 days compared with medical therapy alone?

Jovin et al. (NEJM 2015) · doi:10.1056/NEJMoa1503780 · 206 patients

Population

Included

  • Age 18 to 80 years (extended to 85 years during the trial)
  • Acute ischemic stroke with proximal anterior circulation occlusion (intracranial ICA or M1 MCA)
  • NIHSS of 6 or greater at the time of randomization
  • Pre-stroke functional independence (mRS 0 or 1)
  • Treatment feasible within 8 hours of symptom onset
  • Absence of large infarct on imaging (ASPECTS 7 or greater on CT, or 6 or greater on diffusion MRI)
  • Contraindication to IV alteplase, or failure of alteplase to recanalize after 30 minutes

Excluded

  • Large established infarct on baseline imaging
  • Severe pre-stroke disability
  • Comorbidities or coagulopathy precluding endovascular treatment
  • Pregnancy
  • Symptom onset to randomization beyond 8 hours

Source: ClinicalTrials.gov NCT01692379· Retrieved 2026-06-08

Primary Outcome — mRS Distribution at 90 Days

All randomized patients (anterior circulation LVO, within 8 hours)

Solitaire Thrombectomy + Medical TherapyBetter outcome
43 / 100
Medical Therapy Alone
28 / 100

mRS 0-2 at 90 Days

Risk ratio 1.7095% CI 1.05–2.80p = 0.009

Study Arms

Agent
Solitaire FR stent retriever (Covidien), a self-expanding device to retrieve thrombus and restore flow
Route
Endovascular (mechanical thrombectomy)
Frequency
Single thrombectomy procedure, initiable within 8 h of symptom onset.
Duration
One-time procedure
Co-interventions
Medical therapy including IV alteplase when eligible (given in BOTH arms; eligible patients received alteplase within 4.5 h before randomization; thrombectomy arm entered after no recanalization ≥30 min post-alteplase, or with alteplase contraindication). QI workflow to minimize time to reperfusion.

Design from Jovin NEJM 2015 p.2297. Thrombectomy 98/103; ipsilateral cervical carotid stenting 9; GA 7 (6.7%); 1 IA alteplase + 1 angioplasty after failed retrieval. mTICI 2b/3 66%. Unrestricted Covidien grant. Source: NCT01692379.

Trial Design

Type

  • Randomized trial embedded in a population-based registry
  • Thrombectomy plus medical therapy vs medical therapy alone
  • Anterior circulation LVO without large infarct
  • Treatment window up to 8 hours

Timeline

Conducted at 4 centers in Catalonia, Spain

N

206

Enrollment

Phase 3 RCT embedded in a population-based stroke registry, enrolling 206 patients across 4 Catalan centers between November 2012 and December 2014 (Jovin NEJM 2015). Stopped early after the other 2015 EVT trials reported positive results.

ClinicalTrials.gov

NCT01692379

Bedside Pearl

For an anterior circulation LVO patient between 4.5 and 8 hours from onset, especially when alteplase is contraindicated or has failed, REVASCAT supports proceeding to Solitaire thrombectomy provided ASPECTS is 7 or higher on CT. The functional independence gain is about 15 percentage points (NNT about 7, derived from the secondary mRS 0-2 outcome; the protocol-defined primary was the ordinal mRS shift).

NeuroWiki is a clinical reference. It does not substitute for your clinical judgment, current guidelines, or your institution's protocol. Verify before acting. Do not enter patient names, MRNs, or dates of birth. Privacy Policy